膀胱尿路上皮癌根治性膀胱切除术后变异组织学的系统评价与荟萃分析
该系统评价与荟萃分析纳入39项研究共20,544例接受根治性膀胱切除术的膀胱尿路上皮癌患者,评估变异组织学对预后的影响。结果显示变异组织学与更差的总生存、癌症特异性生存和无复发生存相关,其中微乳头、浆细胞样和小细胞亚型与更差总生存独立相关。
要点
- 变异组织学与更差的总生存(合并HR 1.44)、癌症特异性生存(合并HR 1.37)和无复发生存(合并HR 1.32)相关。
- 微乳头(合并HR 1.20)、浆细胞样(合并HR 2.03)和小细胞(HR 3.32)亚型与更差总生存相关。
- 建议将变异组织学纳入预后工具以指导风险分层、治疗计划和患者咨询。
核心结论
- 膀胱尿路上皮癌中的变异组织学与疾病复发、癌症特异性死亡和总死亡风险增加相关。
- 微乳头、浆细胞样和小细胞变异组织学亚型与总生存独立相关。
研究设计与样本
- 纳入39项研究,共20,544例接受根治性膀胱切除术的膀胱尿路上皮癌患者。
主要发现
- 变异组织学与更差的癌症特异性生存相关(合并HR 1.37,95%CI 1.24-1.50)。
- 变异组织学与更差的总生存相关(合并HR 1.44,95%CI 1.26-1.65)。
- 变异组织学与更差的无复发生存相关(合并HR 1.32,95%CI 1.20-1.45)。
- 微乳头亚型与更差总生存相关(合并HR 1.20,95%CI 1.02-1.41)。
- 浆细胞样亚型与更差总生存相关(合并HR 2.03,95%CI 1.17-3.52);小细胞亚型与更差总生存相关(HR 3.32,95%CI 1.98-5.59)。
关键数值与推荐
- 纳入标准为比较伴或不伴变异组织学的膀胱尿路上皮癌患者的总生存、癌症特异性生存和无复发生存的研究。
临床怎么用
- 将变异组织学纳入预后工具,以指导风险分层、治疗计划和患者咨询。
局限性
- 目标人群存在异质性。
- 所评价的原始数据为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The currently available evidence regarding the prognostic and clinical significance of each variant histology subtype of urothelial bladder cancer remains scarce. We assessed the prognostic value of variant histology in patients with urothelial carcinoma of the bladder treated with radical cystectomy. MATERIALS AND METHODS: PubMed®, Web of Science™, Cochrane Library and Scopus® databases were searched for articles published before October 2019 according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. We identified 39 studies comprising 20,544 patients matching our eligibility criteria. RESULTS: Studies were deemed eligible if they compared overall, cancer specific and recurrence-free survival in patients with urothelial carcinoma of the bladder with and without variant histology. Formal meta-analyses were performed for these outcomes. Variant histology was associated with worse cancer specific (pooled HR 1.37, 95% CI 1.24-1.50), overall (pooled HR 1.44, 95% CI 1.26-1.65) and recurrence-free survival (pooled HR 1.32, 95% CI 1.20-1.45). Subgroup analyses demonstrated that "micropapillary" (pooled HR 1.20, 95% CI 1.02-1.41), "plasmacytoid" (pooled HR 2.03, 95% CI 1.17-3.52) and "small cell" variant histology (HR 3.32, 95% CI 1.98-5.59) were also associated with worse overall survival. CONCLUSIONS: Variant histology in patients with urothelial carcinoma of the bladder is associated with increased risks of disease recurrence as well as cancer specific and overall mortality. Variant histology was independently associated with overall survival in the "micropapillary," "plasmacytoid" and "small cell" subgroups. Variant histology should be integrated into prognostic tools to guide risk stratification, treatment planning and patient counseling. However, caution should be exercised in interpreting the conclusions drawn from this study given the limitations, which include the heterogeneity of the population of interest and the retrospective nature of the primary data evaluated.
引用
- Mori K, Abufaraj M, Mostafaei H, et al. A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. J Urol. 2020. PMID: 32716694. doi:10.1097/JU.0000000000001305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。